All News

As patients pay more healthcare expenses directly from their own pockets, the industry must look at patients' ability to pay alongside willingness to pay to understand the various factors of patient decisions to accept or decline treatment.

Click the title above to open the Pharmaceutical Executive September 2019 issue in an interactive PDF format.

A decade into China’s far-reaching healthcare reforms-which began with the implementation of universal, albeit rudimentary, medical insurance-the pace of change and transformation within the country’s life sciences industry shows no signs of abating.

The latest trends in patent litigation has led to a more harmonized patent system, which can benefit pharmaceutical companies that invest in patents.

Do’s and Dont’s while facing the increased war for talent.

A 2019 study reveals further marginal decline in the pharma industry's reputation. Sven Klingemann suggests some "recovery solutions".

A look at questions that need to be answered regarding drug importation coexisting with the Drug Supply Chain Security Act (DSCSA).

Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.

With Spain enjoying an economic rebound, pharma and medtech multinationals are seeing the country as a top-tier investment destination once more-thanks to improved market access, quality but affordable manufacturing capabilities, and an enviable clinical research base.

Highlighting the biggest observations from this year's DIA Annual Meeting-topics likely to continue to dominate industry headlines for the foreseeable future.

Click the title above to open the Pharmaceutical Executive July 2019 issue in an interactive PDF format.

In the middle of new reforms, and with its political turmoil well in the past, Egypt is striving to open the door to a brave new era of healthcare provision, where improving public healthcare has been assigned priority status.

The opportunities and challenges surrounding patient centricity and patient-centric trials in China.

Our latest rankings and report of the top 50 biopharma companies provides a nice springboard to the coverage we have in store for you in the year's second half.

Successor to current CEO Olivier Brandicourt is announced.

Nominations for the 2019 eyeforpharma awards are currently open.